


bsm-62518R**[Primary Antibody]****HIF1A | HIF1-alpha Recombinant Rabbit mAb****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

— DATASHEET —**Host:** Rabbit**Isotype:** IgG**Clonality:** Recombinant**CloneNo.:** 4H12**GeneID:** 3091**SWISS:** Q16665**Target:** HIF1A | HIF1-alpha**Immunogen:** A synthesized peptide derived from human HIF 1 alpha: 616-674/826.**Purification:** affinity purified by Protein A**Storage:** 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.**Background:** Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia.**Applications:** **WB** (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Flow-Cyt** (1:50-100)**ICC/IF** (1:50-200)**Reactivity:** Human**Predicted
MW.:** 93 kDa**Observed
MW.:** 120 kDa**Subcellular
Location:** Cytoplasm ,Nucleus**— VALIDATION IMAGES —**


Hep-G2 (H) cells were treated with or without CoCl₂ (500uM) for 6 h, 25 µg total protein per lane of cell lysates (see on figure) probed with HIF-1 Alpha monoclonal antibody, unconjugated (bsm-62518R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.




Paraformaldehyde-fixed, paraffin embedded Human Endometrial Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with HIF-1 Alpha Monoclonal Antibody, Unconjugated (bsm-62518R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.




Paraformaldehyde-fixed, paraffin embedded Human Esophageal Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with HIF-1 Alpha Monoclonal Antibody, Unconjugated (bsm-62518R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



4% Paraformaldehyde-fixed HepG2 (H) (HepG2 treated with 500uM CoCl₂ for 6 hours) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (HIF-1 Alpha) monoclonal Antibody, unconjugated (bsm-62518R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-60295G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.



4% Paraformaldehyde-fixed HeLa (H) (HeLa treated with 500uM CoCl₂ for 6 hours) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (HIF-1 Alpha) monoclonal Antibody, unconjugated (bsm-62518R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-60295G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.



The HepG2 (treated with 500uM CoCl₂ for 6 hours) (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C, the cells then were incubated in 5% BSA to block non-specific protein-protein interactions (30 min at r.t.), followed by secondary antibody incubation for 40 min at room temperature. Primary Antibody (green); Rabbit Anti-HIF-1 Alpha antibody (bsm-62518R, 1:100); Isotype Control (orange): Rabbit IgG (bs-0295P). Blank control (black): PBS. Acquisition of 20,000 events was performed.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

— SELECTED CITATIONS —

- **[IF=4.8]** Le Qiu. et al. Study on the mechanism of no. 8 burn ointment in burn treatment based on network pharmacology and experimental verification. FRONT PHARMACOL. 2025 Jul;16: IHC ;Rat. 40761397